Introduction The combination of biomarkers and drugs is the subject of growing interest both from regulators. physicians and companies. This study protocol of a systematic review is aimed to describe available literature evidences about the cost-effectiveness. cost-utility or net-monetary benefit of the use of biomarkers in solid tumour as tools for customising immunotherapy to identi... https://crowssportes.shop/product-category/starter-kit/